Current landscape and perspective of oncolytic viruses and their combination therapies
- PMID: 36095879
- PMCID: PMC9472052
- DOI: 10.1016/j.tranon.2022.101530
Current landscape and perspective of oncolytic viruses and their combination therapies
Abstract
Oncolytic virotherapy has become an important strategy in cancer immunotherapy. Oncolytic virus (OV) can reshape the tumor microenvironment (TME) through its replication-mediated oncolysis and transgene-produced anticancer effect, inducing an antitumor immune response and creating favorable conditions for the combination of other therapeutic measures. Extensive preclinical and clinical data have suggested that OV-based combination therapy has definite efficacy and promising prospects. Recently, several clinical trials of oncolytic virotherapy combined with immunotherapy have made breakthroughs. This review comprehensively elaborates the OV types and their targeting mechanisms, the selection of anticancer genes armed in OVs, and the therapeutic modes of action and strategies of OVs to provide a theoretical basis for the better design and construction of OVs and the optimization of OV-based therapeutic strategies.
Keywords: Anticancer mechanism; Cancer; Oncolytic virus; Therapeutic strategy; Tumor microenvironment.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest None declared.
Similar articles
-
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.Front Immunol. 2023 Dec 15;14:1308890. doi: 10.3389/fimmu.2023.1308890. eCollection 2023. Front Immunol. 2023. PMID: 38169820 Free PMC article. Review.
-
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.Front Immunol. 2022 Aug 25;13:953410. doi: 10.3389/fimmu.2022.953410. eCollection 2022. Front Immunol. 2022. PMID: 36091031 Free PMC article. Review.
-
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.Front Immunol. 2022 Oct 13;13:1012806. doi: 10.3389/fimmu.2022.1012806. eCollection 2022. Front Immunol. 2022. PMID: 36311790 Free PMC article. Review.
-
Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.J Immunother Cancer. 2022 May;10(5):e004167. doi: 10.1136/jitc-2021-004167. J Immunother Cancer. 2022. PMID: 35640930 Free PMC article. Review.
-
Immune landscape and response to oncolytic virus-based immunotherapy.Front Med. 2024 Jun;18(3):411-429. doi: 10.1007/s11684-023-1048-0. Epub 2024 Mar 8. Front Med. 2024. PMID: 38453818 Review.
Cited by
-
Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions.Asian J Pharm Sci. 2023 Jan;18(1):100771. doi: 10.1016/j.ajps.2022.100771. Epub 2022 Dec 29. Asian J Pharm Sci. 2023. PMID: 36896445 Free PMC article. Review.
-
Simultaneous Expression of Different Therapeutic Genes by Infection with Multiple Oncolytic HSV-1 Vectors.Biomedicines. 2024 Jul 16;12(7):1577. doi: 10.3390/biomedicines12071577. Biomedicines. 2024. PMID: 39062150 Free PMC article.
-
Exploring the genetic associations and causal relationships between antibody responses, immune cells, and various types of breast cancer.Sci Rep. 2024 Nov 19;14(1):28579. doi: 10.1038/s41598-024-79521-w. Sci Rep. 2024. PMID: 39562684 Free PMC article.
-
Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases.Oncol Lett. 2024 Apr 3;27(6):244. doi: 10.3892/ol.2024.14377. eCollection 2024 Jun. Oncol Lett. 2024. PMID: 38638849 Free PMC article.
-
Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.J Microbiol. 2024 Jul;62(7):491-509. doi: 10.1007/s12275-024-00159-4. Epub 2024 Jul 22. J Microbiol. 2024. PMID: 39037484 Review.
References
-
- Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 1997;3(6):639–645. doi: 10.1038/nm0697-639. Jun. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources